NO314090B1 - HIV-proteingenekspresjonsenhet, DNA-vektor som omfatter den, Drosophila-celle transfektert med vektoren, HIV gp 120 og HIV gp 160-proteinprodusert i en kultur av nevnte celler, vaksine og diagnostisk agens som omfatterproteinet, samtfremgangs - Google Patents

HIV-proteingenekspresjonsenhet, DNA-vektor som omfatter den, Drosophila-celle transfektert med vektoren, HIV gp 120 og HIV gp 160-proteinprodusert i en kultur av nevnte celler, vaksine og diagnostisk agens som omfatterproteinet, samtfremgangs Download PDF

Info

Publication number: NO314090B1
Authority: NO; Norway
Prior art keywords: protein; hiv; cells; vector; gene expression
Prior art date: 1988-12-01

Application number

NO19912099A

Other languages

English (en)

Norwegian (no)

Other versions

NO912099D0 (no

NO912099L (no

Inventor

Hanne Ranch Johansen

Martin Rosenberg

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-01

Filing date

1991-05-31

Publication date

2003-01-27

1991-05-31 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1991-05-31 Publication of NO912099D0 publication Critical patent/NO912099D0/no

1991-07-31 Publication of NO912099L publication Critical patent/NO912099L/no

2003-01-27 Publication of NO314090B1 publication Critical patent/NO314090B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims description 114
102000004169 proteins and genes Human genes 0.000 title claims description 82
230000014509 gene expression Effects 0.000 title claims description 57
239000013598 vector Substances 0.000 title claims description 56
241000255581 Drosophila <fruit fly, genus> Species 0.000 title claims description 25
229960005486 vaccine Drugs 0.000 title claims description 11
239000000032 diagnostic agent Substances 0.000 title claims description 6
229940039227 diagnostic agent Drugs 0.000 title claims description 6
238000000034 method Methods 0.000 claims description 35
230000027455 binding Effects 0.000 claims description 24
238000004519 manufacturing process Methods 0.000 claims description 20
108091026890 Coding region Proteins 0.000 claims description 19
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 claims description 17
108020004414 DNA Proteins 0.000 claims description 14
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 10
102000003792 Metallothionein Human genes 0.000 claims description 10
108090000157 Metallothionein Proteins 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
238000013518 transcription Methods 0.000 claims description 8
230000035897 transcription Effects 0.000 claims description 8
230000001105 regulatory effect Effects 0.000 claims description 7
239000011347 resin Substances 0.000 claims description 7
229920005989 resin Polymers 0.000 claims description 7
102000007469 Actins Human genes 0.000 claims description 5
108010085238 Actins Proteins 0.000 claims description 5
241000238631 Hexapoda Species 0.000 claims description 5
238000001514 detection method Methods 0.000 claims description 5
239000000463 material Substances 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 4
101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 claims description 3
101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 claims description 3
238000013519 translation Methods 0.000 claims description 3
230000002480 immunoprotective effect Effects 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
230000004224 protection Effects 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims 1
210000004027 cell Anatomy 0.000 description 109
241000725303 Human immunodeficiency virus Species 0.000 description 50
150000001413 amino acids Chemical class 0.000 description 31
108090000288 Glycoproteins Proteins 0.000 description 20
102000003886 Glycoproteins Human genes 0.000 description 20
239000012634 fragment Substances 0.000 description 18
101800001690 Transmembrane protein gp41 Proteins 0.000 description 16
241000700605 Viruses Species 0.000 description 16
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 15
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 15
229940097277 hygromycin b Drugs 0.000 description 15
238000000746 purification Methods 0.000 description 15
239000002609 medium Substances 0.000 description 14
239000013612 plasmid Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
239000000872 buffer Substances 0.000 description 12
239000000427 antigen Substances 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
208000031886 HIV Infections Diseases 0.000 description 10
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 10
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 10
238000005259 measurement Methods 0.000 description 10
229960000187 tissue plasminogen activator Drugs 0.000 description 10
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
229960000485 methotrexate Drugs 0.000 description 9
238000001262 western blot Methods 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
238000001890 transfection Methods 0.000 description 8
241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
229920002684 Sepharose Polymers 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
239000003636 conditioned culture medium Substances 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
108010022394 Threonine synthase Proteins 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
230000004927 fusion Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
239000011534 wash buffer Substances 0.000 description 6
210000005253 yeast cell Anatomy 0.000 description 6
238000004113 cell culture Methods 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
102000004419 dihydrofolate reductase Human genes 0.000 description 5
108700004025 env Genes Proteins 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000002245 particle Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
241000701447 unidentified baculovirus Species 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
101150074155 DHFR gene Proteins 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
101150116497 sacm1l gene Proteins 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
101150030339 env gene Proteins 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000004114 suspension culture Methods 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
241001599018 Melanogaster Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101150008132 NDE1 gene Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
238000003149 assay kit Methods 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000012411 cloning technique Methods 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
101150010939 tpa gene Proteins 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
101100217199 Arabidopsis thaliana ARV2 gene Proteins 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000255597 Drosophila hydei Species 0.000 description 1
101000756630 Drosophila melanogaster Actin-5C Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229940033332 HIV-1 vaccine Drugs 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
101001116388 Homo sapiens Melatonin-related receptor Proteins 0.000 description 1
101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
101150042441 K gene Proteins 0.000 description 1
229940122920 Kallikrein inhibitor Drugs 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
101100268515 Mus musculus Serpina1b gene Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
208000020584 Polyploidy Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102100025421 Serine protease inhibitor Kazal-type 6 Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940069078 citric acid / sodium citrate Drugs 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000012248 genetic selection Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000012007 large scale cell culture Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000017960 syncytium formation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/75—Vector systems having a special element relevant for transcription from invertebrates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Virology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19912099A 1988-12-01 1991-05-31 HIV-proteingenekspresjonsenhet, DNA-vektor som omfatter den, Drosophila-celle transfektert med vektoren, HIV gp 120 og HIV gp 160-proteinprodusert i en kultur av nevnte celler, vaksine og diagnostisk agens som omfatterproteinet, samtfremgangs NO314090B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27838688A	1988-12-01	1988-12-01
PCT/US1989/005155 WO1990006358A1 (fr)	1988-12-01	1989-11-29	EXPRESSION DE PROTEINES HIV DANS DES CELLULES DE $i(DROSOPHILA)

Publications (3)

Publication Number	Publication Date
NO912099D0 NO912099D0 (no)	1991-05-31
NO912099L NO912099L (no)	1991-07-31
NO314090B1 true NO314090B1 (no)	2003-01-27

Family

ID=23064787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19912099A NO314090B1 (no)	1988-12-01	1991-05-31	HIV-proteingenekspresjonsenhet, DNA-vektor som omfatter den, Drosophila-celle transfektert med vektoren, HIV gp 120 og HIV gp 160-proteinprodusert i en kultur av nevnte celler, vaksine og diagnostisk agens som omfatterproteinet, samtfremgangs

Country Status (12)

Country	Link
EP (1)	EP0446272A4 (fr)
JP (1)	JP3085704B2 (fr)
KR (1)	KR0152525B1 (fr)
AU (1)	AU630649B2 (fr)
CA (1)	CA2003794C (fr)
DK (1)	DK175461B1 (fr)
FI (1)	FI113475B (fr)
IL (1)	IL92470A (fr)
NO (1)	NO314090B1 (fr)
PT (1)	PT92477A (fr)
WO (1)	WO1990006358A1 (fr)
ZA (1)	ZA899150B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2841376C (fr) *	2011-07-05	2023-02-28	Duke University	Immunogenes gp120 a extremite n-terminale deletee
WO2013052095A2 (fr)	2011-10-03	2013-04-11	Duke University	Vaccin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0272858A3 (fr) *	1986-12-15	1989-07-12	Repligen Corporation	Protéines recombinantes d'enveloppe du HIV, produites dans des cellules d'insectes
CA1341345C (fr) *	1987-05-08	2002-03-05	Hanne Ranch Johansen	Expression de genes etrangers dans des cellules de drosophile
AP129A (en) *	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
KR910700352A (ko) *	1988-12-21	1991-03-14	스미스클라인 바이올로지칼즈(s.a.)	곤충 세포내에서 플라스모듐 서컴스포로 조이트 단백질의 발현

1989
- 1989-11-24 CA CA002003794A patent/CA2003794C/fr not_active Expired - Lifetime
- 1989-11-27 IL IL9247089A patent/IL92470A/xx not_active IP Right Cessation
- 1989-11-29 EP EP19900900559 patent/EP0446272A4/en not_active Withdrawn
- 1989-11-29 WO PCT/US1989/005155 patent/WO1990006358A1/fr active IP Right Grant
- 1989-11-29 JP JP02500753A patent/JP3085704B2/ja not_active Expired - Lifetime
- 1989-11-29 AU AU47552/90A patent/AU630649B2/en not_active Expired
- 1989-11-29 KR KR1019900701678A patent/KR0152525B1/ko not_active IP Right Cessation
- 1989-11-30 ZA ZA899150A patent/ZA899150B/xx unknown
- 1989-11-30 PT PT92477A patent/PT92477A/pt not_active Application Discontinuation
1991
- 1991-05-31 FI FI912635A patent/FI113475B/fi active
- 1991-05-31 DK DK104991A patent/DK175461B1/da not_active IP Right Cessation
- 1991-05-31 NO NO19912099A patent/NO314090B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0446272A1 (fr)	1991-09-18
AU4755290A (en)	1990-06-26
CA2003794A1 (fr)	1990-06-01
WO1990006358A1 (fr)	1990-06-14
PT92477A (pt)	1990-06-29
NO912099D0 (no)	1991-05-31
AU630649B2 (en)	1992-11-05
EP0446272A4 (en)	1993-01-07
CA2003794C (fr)	2000-02-08
KR910700344A (ko)	1991-03-14
DK175461B1 (da)	2004-11-01
FI113475B (fi)	2004-04-30
IL92470A0 (en)	1990-08-31
IL92470A (en)	1997-01-10
KR0152525B1 (ko)	1998-10-01
NO912099L (no)	1991-07-31
JPH04501954A (ja)	1992-04-09
DK104991A (da)	1991-05-31
DK104991D0 (da)	1991-05-31
JP3085704B2 (ja)	2000-09-11
FI912635A0 (fi)	1991-05-31
ZA899150B (en)	1991-04-24

Publication	Publication Date	Title
Culp et al.	1991	Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells
Earl et al.	1997	Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein
US6080408A (en)	2000-06-27	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US6090392A (en)	2000-07-18	HIV envelope polypeptides and vaccine
US5955342A (en)	1999-09-21	Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5795577A (en)	1998-08-18	Viral vector coding for a glycoprotein of the virus responsible for A.I.D.S.
JP2004537974A (ja)	2004-12-24	改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
Berman et al.	1989	Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160
CA2338886C (fr)	2011-10-04	Expression et caracterisation d'une proteine d'enveloppe vih-1 associee a une reponse d'anticorps de neutralisation largement reactifs
WO1998041536A9 (fr)	1999-03-04	Glycoproteines enveloppes de vih et vis a glycosylation deficiente
US5681713A (en)	1997-10-28	Expression of heterologous proteins in Drosophila cells
Corbet et al.	2000	Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons
EP2118125B1 (fr)	2011-10-26	Conjugués de complément peptidique
NO314090B1 (no)	2003-01-27	HIV-proteingenekspresjonsenhet, DNA-vektor som omfatter den, Drosophila-celle transfektert med vektoren, HIV gp 120 og HIV gp 160-proteinprodusert i en kultur av nevnte celler, vaksine og diagnostisk agens som omfatterproteinet, samtfremgangs
US5550043A (en)	1996-08-27	Expression of heterologous proteins in Drosophila cells
JP5290576B2 (ja)	2013-09-18	修飾されたｈｉｖ−１エンベロープタンパク質
WO1992006212A1 (fr)	1992-04-16	Expression amelioree de proteines virales dans des cellules de drosophila
EP0322394A2 (fr)	1989-06-28	Expression des protéines de HIV dans E.coli et S.cerevisiae
US7090848B1 (en)	2006-08-15	HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
Hobman et al.	1994	Expression of soluble forms of rubella virus glycoproteins in mammalian cells
WO1996027012A1 (fr)	1996-09-06	Antigenes specifiques du vih-1, groupe o
Bäyon-Auboyer et al.	1994	Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques
WO1995032000A1 (fr)	1995-11-30	Immunogenes de polyproteines de vih
EP0588750A2 (fr)	1994-03-23	Procédé pour la production de polypeptides recombinants contenant des épitopes dérivées d'isolées d'HIV différentes, leur utilisations comme immunigènes et pour la détection d'anticorps contre le HIV
Protection	0	Vaccination of Rhesus Macaques with

Legal Events

Date	Code	Title	Description
2009-12-21	MK1K	Patent expired